Cyclopharm (ASX:CYC) has announced it has entered into an interim agreement to supply the Veterans Health Administration, the most extensive integrated government healthcare system in the US, with the pharmaceutical and consumable components of Technegas.
-
AusBiotech
Federal Minister for Health and Aged Care to speak at Australia’s biggest week in biotech
October 8, 2024 -
Latest News
Chimeric says cancer patient achieves complete response in CHM CORE-NK trial
October 8, 2024 -
Latest News
Island Pharmaceuticals secures new funding to support key inflection points and pipeline build
October 8, 2024
-
Latest News Cyclopharm signs agreement makes major progress with US veterans and defence administrations October 8, 2024
-
Latest News New drug could be answer to an overlooked yet devastating type of dementia October 8, 2024Monash University researchers are assessing a new drug that researchers believe could have an impact on a form of dementia.
-
Latest News New Alliance to drive increased procurement of homegrown medtech October 3, 2024The Australian Medtech Manufacturing Alliance has been established with the goal of growing opportunities for medtech manufacturers to sell to health services.
-
Latest News Australian company Vaxxas receives significant investment from Endpoints Capital October 3, 2024Life sciences financier Endpoints Capital has advanced pioneering Australian firm Vaxxas $9.7 million for its Research and Development Tax Incentive.
-
Latest News Nyrada’s says lead drug candidate demonstrates significant cardioprotection October 3, 2024Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.
-
Latest News Cartherics raises over $15 million in private financing round October 3, 2024CEO Professor Alan Trounson AO said, “The successful capital raising, in times of scant investment support in biotechnology, is welcome and further supports confidence in the company for the delivery of effective therapies in ovarian cancer and other difficult diseases.”
-
Latest News Artrya submits application for Salix to the US FDA October 1, 2024Australian medical technology company Artrya (ASX:AYA) has submitted its application for regulatory approval for the Salix Coronary Anatomy product to the US FDA.
-
AusBiotech AusBiotech welcomes more new members from across Australia's life sciences ecosystem October 1, 2024AusBiotech has always been for its members. Built by our members, to be the national voice of our sector we are proud to support our member's growth and leverage our national convening power to shape policy, foster knowledge sharing, and collaborate to advance life sciences in our country. Together, we work to help our members thrive.
-
Latest News Mesoblast option to issue up to US$50 million convertible notes for product launch October 1, 2024Cell therapy company Mesoblast (ASX:MSB) has entered into a convertible note subscription agreement with its largest shareholder, Gregory George, to issue up to US$50 million convertible notes at its discretion.
-
Latest News PolyNovo announces the retirement of long-term non-executive director October 1, 2024PolyNovo chairman David Williams said, "After 14 years Bruce has selflessly decided to stand aside to make way for new blood and concentrate on his other Board roles. He will be missed but I am confident he will still be available for his sage advice."
-
Latest News Percheron Therapeutics updates on Avicursen primate toxicology study October 1, 2024Percheron Therapeutics (ASX:PER) has announced the completion of a nine-month toxicology study in non-human primates for its lead program, avicursen.
-
Latest News Chimeric announces new collaboration with Achieve Clinics September 25, 2024Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a partnership with US-based Achieve that aims to improve patient access to autologous cell therapies.
-
AusBiotech Insights to Innovation: Bridging the funding gap - AusBiotech’s Voice on Investment Survey 2024 September 25, 2024AusBiotech’s biotech and medtech members are being invited to complete the organisation’s first annual AusBiotech Voice on Investment Survey.
-
Latest News Opyl announces the signing of new service agreement with BioIntelect September 25, 2024Opyl (ASX:OPL) has announced a new agreement with clinical research organisation and strategic planning and commercialisation advisory firm Biointelect.
-
Latest News Lumos awarded national contract with MediGroup for FebriDx September 25, 2024Lumos Diagnostics (ASX:LDX) has been awarded placement of their novel point-of-care test, FebriDx, on the MediGroup national contract, making it available to all their members in the United States.
-
Latest News Argenica reports positive results in IND-enabling trials September 25, 2024Argenica Therapeutics (ASX:AGN) has announced the completion of crucial safety studies that are required to be included in its IND application.
-
Latest News New research reveals poor outcomes from advanced prostate cancer could be reversed with targeted treatment September 19, 2024New research findings reveal that people who inherit a genetic biomarker known to predict poorer outcomes with routine prostate cancer treatment could be successfully treated and have better survival outcomes with personalised hormonal therapy.
New Stories
-
Federal Minister for Health and Aged Care to speak at Australia’s biggest week in biotech
October 8, 2024 - - AusBiotech -
Chimeric says cancer patient achieves complete response in CHM CORE-NK trial
October 8, 2024 - - Latest News -
Cyclopharm signs agreement makes major progress with US veterans and defence administrations
October 8, 2024 - - Latest News -
Island Pharmaceuticals secures new funding to support key inflection points and pipeline build
October 8, 2024 - - Latest News -
New drug could be answer to an overlooked yet devastating type of dementia
October 8, 2024 - - Latest News -
New Alliance to drive increased procurement of homegrown medtech
October 3, 2024 - - Latest News -
Australian company Vaxxas receives significant investment from Endpoints Capital
October 3, 2024 - - Latest News